Skip to content
DraconiticResearch
Search Sources API
194,161 studies31 sourcesUpdated 24 min ago
Peer-reviewedCC BY 4.0Frontiers in Immunology

Chemokine–receptor axes in immune–tumor cell communication: spatial niches, immune exclusion, and therapy resistance

  • Yimin Han1
  • Qun liu2
  • Fenghua Ao3
  • Jianrui Huang2
  • Hongmin Lin1
  1. 1The First Hospital of Putian
  2. 2Department of Neurosurgery, Heze Municipal Hospital
  3. 3Department of Neurosurgery, The First Affiliated Hospital of Dali University
Read full textPDFDOICite

Abstract

Chemokine–receptor axes are traditionally viewed as leukocyte trafficking cues, but increasing evidence indicates that they also function as spatial and functional organizers of immune–tumor communication. In the tumor microenvironment, chemokine gradients determine which immune-cell subsets are recruited, where they are positioned, and whether they acquire antitumor or suppressive states. This review summarizes experimentally validated chemokine–receptor axes that shape spatial niches, immune exclusion, and therapy resistance in cancer. The CXCL12–CXCR4 axis serves as a prototype of stromal immune exclusion, particularly in pancreatic cancer, where CXCR4 blockade can improve immune accessibility but may require myeloid-directed combinations. CXCR2 ligand axes, including CXCL5–CXCR2 and IL-8/CXCR2 signaling, promote neutrophil-rich suppressive niches, CD8 ⁺ T-cell dysfunction, PD-L1 induction, and resistance to immune checkpoint blockade or chemotherapy. The CCL20–CCR6 axis recruits regulatory T cells and contributes to metastatic immune suppression, whereas CCL5–CCR5 signaling organizes perivascular macrophage niches and supports adaptive therapy resistance. CCL2-associated macrophage circuits further link monocyte recruitment, TAM polarization, and immunotherapy responsiveness. We discuss how single-cell and spatial technologies can validate these circuits and guide biomarker-driven therapies. Rather than targeting isolated ligand–receptor pairs, future strategies should reprogram chemokine-controlled immune ecosystems to overcome immune exclusion and treatment resistance.

Related

  1. Spatial cell-cell communication inference based on cell-spot-ligand-receptor heterogeneous graphs
    Xiong Li, Dongding Wu, Yuejin Zhang +2
    PLOS Computational BiologyPeer-reviewedCC BY 4.0Full textBioinformatics & computational biologyCell biologyPLOS
  2. Spatial ligand–receptor circuits in osteosarcoma: immune resistance in bone and lung niches
    Yijian Qiu, Shuai Deng, Junfeng Zhou +5
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textOncologyCrossrefEurope PMCPMC
  3. Atypical chemokine receptor 3 regulates synaptic removal in disease astrocytes
    Veronica Giusti, Jungjoo Park, Elena Giusto +16
    Molecular NeurodegenerationPeer-reviewedCC BY5 citedNeurologyOpenAlex
  4. The chemokine receptor‐like fourth extracellular loop of the apelin receptor differentially regulates apelin and elabela binding and signalling
    Chloé Bonef, Hela Bouhsine, Carine Huynh +9
    British Journal of PharmacologyPeer-reviewedCC BY 4.0Full textGeneral biochemistryGeneral biologyHAL
  5. Distinct atypical chemokine receptor 1 determinants underlie bacterial toxins recognition and pore formation
    A. Fouillen, E. Logerot, Z. Ammar +10
    bioRxivPreprintCC BY-NC-NDFull textOncologybioRxiv

Cite

BibTeXRIS
BibTeX
@article{han2026chemokinereceptor,
  title = {{Chemokine–receptor axes in immune–tumor cell communication: spatial niches, immune exclusion, and therapy resistance}},
  author = {Yimin Han and Qun liu and Fenghua Ao and Jianrui Huang and Hongmin Lin},
  journal = {Frontiers in Immunology},
  year = {2026},
  month = oct,
  doi = {10.3389/fimmu.2026.1879293},
  url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1879293/full},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Chemokine–receptor axes in immune–tumor cell communication: spatial niches, immune exclusion, and therapy resistance
AU  - Yimin Han
AU  - Qun liu
AU  - Fenghua Ao
AU  - Jianrui Huang
AU  - Hongmin Lin
PY  - 2026
DA  - 2026/10/09
JO  - Frontiers in Immunology
DO  - 10.3389/fimmu.2026.1879293
UR  - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1879293/full
AB  - Chemokine–receptor axes are traditionally viewed as leukocyte trafficking cues, but increasing evidence indicates that they also function as spatial and functional organizers of immune–tumor communication. In the tumor microenvironment, chemokine gradients determine which immune-cell subsets are recruited, where they are positioned, and whether they acquire antitumor or suppressive states. This review summarizes experimentally validated chemokine–receptor axes that shape spatial niches, immune exclusion, and therapy resistance in cancer. The CXCL12–CXCR4 axis serves as a prototype of stromal immune exclusion, particularly in pancreatic cancer, where CXCR4 blockade can improve immune accessibility but may require myeloid-directed combinations. CXCR2 ligand axes, including CXCL5–CXCR2 and IL-8/CXCR2 signaling, promote neutrophil-rich suppressive niches, CD8 ⁺ T-cell dysfunction, PD-L1 induction, and resistance to immune checkpoint blockade or chemotherapy. The CCL20–CCR6 axis recruits regulatory T cells and contributes to metastatic immune suppression, whereas CCL5–CCR5 signaling organizes perivascular macrophage niches and supports adaptive therapy resistance. CCL2-associated macrophage circuits further link monocyte recruitment, TAM polarization, and immunotherapy responsiveness. We discuss how single-cell and spatial technologies can validate these circuits and guide biomarker-driven therapies. Rather than targeting isolated ligand–receptor pairs, future strategies should reprogram chemokine-controlled immune ecosystems to overcome immune exclusion and treatment resistance.
SN  - 1664-3224
ER  -